



President: Dr Chris Gouws / Secretary: Dr Rian Viljoen / Treasurer: Dr Jaco Maartens
 Email: savrssecretary@gmail.com Fax 0866 188 640

SAVRS guidelines for the Management of Diabetic Macular Oedema

The Academic Advisory Committee of the SA Vitreoretinal Society (SAVRS) would like to review the guideline for the management of Diabetic Macular Oedema (DMO). The purpose of these guidelines is to advise ophthalmologists and funders. The committee would like to record the following points:

1. Diabetic macular oedema is the leading cause of irreversible visual loss in those under 65 years of age. It is a chronic condition that requires life-long management. Diabetic maculopathy is a PMB condition (904B in the CMS PMB Coded List 2013.) ICD10 applicable codes H35.0; H35.2; H35.3; H35.8; H36.0, E11.3; E10.3.
2. The Council for Medical Schemes (COMS) updated PMB ICD 10 Coded list for 2013 for the treatment of 904B conditions under which Diabetic Macular Oedema is grouped with other unrelated conditions refers to a schedule of diagnosis and treatment pairs dated 1998. In the PMB list, the treatment options listed are therefore outdated and are no longer the current level of care. The treatment options listed for the whole group of 904B conditions is "vitrectomy surgery, laser surgery, other surgery". Different and new treatment options are required to be used by qualified ophthalmologists registered with the HPCSA. In fact, not to treat appropriately would make the ophthalmologist medico-legally liable for outdated care of their patients. Therefore this SAVRS guideline is a brief attempt to guide current ophthalmologists and funders with the current state of treatment. It would therefore be indefensible for an ophthalmologist in terms of the Medical Schemes Act and HPCSA regulations to refer to COMS 1998 treatments and this likewise applies to funders.
3. Anti-VEGF monotherapy with Ranibizumab (Lucentis®) or Aflibercept (Eylea) intra-vitreous injections are the current standard of care for the management of Diabetic maculopathy causing Diabetic macular oedema (DMO) resulting in vision loss due to centre involvement, as demonstrated by multiple international, multi-centre, randomised controlled trials in peer reviewed journals (Level 1 evidence)^{1,2,3,4}. Guidelines for treatment are detailed in Appendix 1. Ranibizumab (Lucentis®) is registered internationally and locally in South Africa by the MCC for the treatment of DMO and Eylea is awaiting local registration.
4. Bevacizumab (Avastin®) carries international registration and MCC registration for the treatment of carcinoma of the colon but is NOT registered for use in the eye in South Africa. The use of Bevacizumab (Avastin®) for the management of DMO is therefore in an "off-label" capacity when used intravitreally in SA. This is despite evidence that it is efficacious for this indication and substantiated in the literature (Level 1 evidence)^{5,10,11}. The decision to use Bevacizumab (Avastin®) is in most cases dictated by funders and may not be the first choice of the treating surgeon.
5. Bevacizumab (Avastin®) is packaged in a single, sterile vial for use as an intravenous agent. The fluid contents of each vial are commonly compounded into smaller quantities in order to make the unit cost more affordable. In other countries where Bevacizumab (Avastin®) is used, compounding pharmacies undertake the process of preparing the units under strict aseptic conditions. Where such a pharmacy is not available

locally in South Africa, the local pharmacists or surgeon will need to perform the compounding process themselves. In the absence of a compounding pharmacy, the SAVRS recommends that the compounding is performed by a pharmacist or surgeon under a laminar flow hood suitable for preparation of sterile intravenous medication, or, in the absence of a laminar flow unit, under strict sterile conditions in an operating theatre. Compounding costs are expected to vary amongst treatment centres with differing usage patterns, facility costs and other economic determinants.

6. Where funders have not consulted the appropriate South African specialist opinion (SAVRS), funders have used guidelines from other countries. Most commonly the comprehensive Royal College of Ophthalmologists guideline has been used⁷. This excellent guideline has not, in many instances, been applied appropriately by funders to the South African situation. This is because funders are not aware that NICE (National Institute for Health and Care Excellence, United Kingdom), which oversees the use of treatments in the British National Health System (NHS) does not authorise the use of Avastin for intraocular use in the NHS.
7. Note that DME (Edema - American English) and DMO are used interchangeably in the literature.
8. Appendix 2: Codes

APPENDIX 1: Recommended treatment for diabetic macular oedema (DMO).

1. Patients should be referred to a suitably trained ophthalmologist for treatment.
2. Diagnosis of DMO should be confirmed by the ophthalmologist and baseline visual acuity should be recorded⁷. Where there is vision loss, treatment should be discussed and offered, unless contra-indicated, for all levels of vision.
3. Current standard of care recommendations include the performing of a fluorescein angiogram of the eye at baseline to confirm the diagnosis and assess the degree of capillary non-perfusion. The fluorescein angiogram is performed either in a hospital or at the doctor's rooms depending on the doctor's discretion. Repeat angiography may be required to assess response to treatment or unexplained visual loss.
4. The Optical Coherence Tomography (OCT) (code 3028) scan is an essential investigation for the diagnosis and follow-up of the therapy⁷.
5. **For DMO with centre involvement causing vision loss**, the current guideline (Level 1 evidence) dictates treatment with anti-VEGF monotherapy^{1,2,7}. This initiation of therapy is similar to AMD, starting on a monthly basis. During this initiation phase of treatment, re-assessment with visual acuity (VA) and OCT is required and this may be required at least monthly. Once the vision has stabilised after treatment for at least two consecutive monthly visits, the treatment is stopped but monitoring should be continued on a monthly basis. If the VA deteriorates due to DMO, then monthly injections should be restarted until a stable VA is again attained. Alternative maintenance strategies that are similar to treat and extend protocols used in Age-related Macular Degeneration, are emerging as options in DME treatment as well. This approach allows for a reduced number of visits and injections in the long-term while maintaining visual outcomes^{12,13}.
6. The place where the injection is performed is in a suitable sterile environment which may either be in a hospital setting or in the doctor's rooms depending on the treating doctor's discretion⁶.
7. The role of adjunctive laser (focal or grid) is currently unclear in the short term though long-term data have shown a reduction in the number of intravitreal treatments when combined with laser^{1,9}. As VA improvement following laser treatment occurs slowly, this effect may still be seen in the long term and the outcome of current trials is awaited⁹.
8. Because funders are interpreting the NICE and Royal College of Ophthalmologists guidelines themselves, the following needs to be clarified:
 - Reference is made in the Royal College of Ophthalmologists guidelines to the NICE use of 400 microns as the central retinal thickness (CRT) at which to initiate the induction of Lucentis intravitreal treatment. This is a NICE recommendation for the use of Lucentis and does not have level 1 evidence. It refers to a subset of patients in the original RCT of Lucentis who had better visual outcomes but the RCT were not powered to make this analysis¹.

9. Where there is **DMO with centre involvement of the macula but no vision loss**, the patient requires observation and treatment according to ETDRS guidelines - see below (Level A recommendation).
10. Where there is **DME with no centre involvement**, the patient requires treatment according to ETDRS guidelines (Level A recommendation)^{1,8}.
 - Summary of ETDRS guidelines: Focal photocoagulation: Treatment of individual micro aneurysms that fill with fluorescein and/or leak
 - Grid laser: treatment of areas of thickened retina showing diffuse fluorescein leakage and / or capillary dropout.
11. Systemic management of the patient is critical to achieving optimum visual outcome and improvement of the DMO and therefore must be optimised by monitoring systemic factors under the guidance of a Diabetic clinic or Diabetologist on a regular basis.
12. This guideline covers DMO and not proliferative diabetic retinopathy. However, caution is advised when proliferation is present as accelerated fibrosis may be precipitated by injection of anti-VEGF agents and this may lead to vision loss.
13. Non-responders to the primary anti-VEGF monotherapy require alternative treatment options. This would include changing to another anti-VEGF agent (Lucentis, Eylea) which have a different mode of action. Further options include retinal laser or intravitreal steroids⁷. (dexamethasone 700 µg intravitreal implant, Ozurdex).
14. Intravitreal steroids (Ozurdex) have been found to be valuable second line agents^{14, 15}. The early best corrected visual acuity (BCVA) response to intravitreal anti-VEGF therapy is significantly associated with longterm visual acuity outcome. Thus after three loading doses of anti-VEGF, a poor BCVA gain would be an indication to switch to second line therapy¹⁴. Intravitreal steroids have the advantage of requiring fewer injections due to the longer duration of action (variable, but 3 – 5 months duration).
15. Because DME is the complication of a systemic condition, it is expected that the rate of bilateral cases requiring treatment will be higher.
16. Cataract surgery on patients with previous/current DMO may exacerbate the oedema. Consideration should be given to the use of anti-VEGF agents at the time of cataract surgery in selected patients.

References:

1. New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. *Eye* 2012; 26: 485-493. Bandello *et al*.
2. Intravitreal Ranibizumab for DME with prompt vs deferred laser- 5 year RCT results. *Ophthalmol* 2015; 122: 375-381. Elman *et al*.
3. Long term effects of therapy with Ranibizumab on diabetic retinopathy - severity and baseline risk factors for worsening retinopathy. *Ophthalmol* 2015; 122: 367-384. Ip *et al*.
4. What have we learnt about the management of DME in the anti-VEGF and corticosteroid era? *Current opin Ophthalmol* 2015; 26: 177-183. Argawal *et al*.
5. A prospective RCT of intravitreal Bevacizumab or Laser therapy in the management of DME (BOLT study). *Ophthalmol* 2010; 117(6): 1078-1086. Michaelides *et al*.
6. Intravitreal injections: is there benefit for a theatre setting? *Br J Ophthalmol* 2012;96: 1474-1478. Abell *et al*.
7. Diabetic Retinopathy Guidelines. Royal College of Ophthalmologists. Section 11: 96-118. (Reviewed Dec 2015).
8. Clinical guidelines for diabetic retinopathy - a summary. Royal College of Ophthalmologists. *Eye* 2013; 27: 285-287.
9. Management of DME: Is it time to say goodbye to macular laser? *Int Ophthalmol Clin* 2015; 55(4) 113-122. Chen *et al*.
10. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. *N Engl J Med* 2015; 372(13): 1193-203. The Diabetic Retinopathy Clinical Research Network.
11. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment. *JAMA Ophthalmol* 2016; 134(8):888-895. Ross *et al* for the Diabetic Retinopathy Clinical Research Network.
12. Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network. *Curr Opin Ophthalmol* 2016, 27: 210-216. Baker *et al*.

13. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. *Br J Ophthalmol* 2015; 0: 1-9. Prunte *et al.*
14. Early and Long-Term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of protocol 1 data. *Am J Ophthalmol* 2016;172:72-79. Victor H. Gonzalez *et al.*
15. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (Euretina). *Ophthalmologica* 2017;237:185-222. Ursula Schmidt-Erfurth *et al.*

2018

SAVRS Academic Advisory Committee:

Dr J Acton

Dr R Amod

Dr J Miller

Dr J Rice

Dr K Roelofse

Dr R Scholtz

Dr K Suttle

Dr L Visser

APPENDIX 2: RETINAL CODES

Initial Diagnosis:

| | |
|-------------------|---|
| 0190 | Consultation |
| 3009 | Basic Capital Equipment |
| 3014 | Tonometry |
| 3003 | Fundus Examination with Diagnostic Lens |
| 3027 | Fundus Photography |
| 3028 | Optic Coherence Tomography (OCT) |
| 3022 3024 3027 | Angiography – Fluorescein (with 0190 if interpreted and explained on a separate occasion) |
| No code yet | OCT Angiography |
| 3041 & 3039, 3201 | Retinal laser – Macular or PRP |

Follow-Up and Maintenance Tests:

| | |
|------|---|
| 0190 | Consultation |
| 3009 | Basic Capital Equipment |
| 3003 | Fundus Examination with Diagnostic Lens |
| 3027 | Fundus Photography x 1 per year |
| 3028 | Optical Coherence Tomography (OCT), monthly until stable and then extend follow-ups |

Injection procedure:

| | |
|---|--|
| 3090 | |
| 3035 | |
| Facility fee Hospital | |
| Rooms procedure – disposables: 0201 (needles, gloves, drape, local anaesthetic, cleaning materials, sterile pack) Avastin / anti-VEGF | |

SAVRS Management of DMO

February 2018

| PMB Conditions | DMO E10.3, E11.3, H36.0, H35.8 | Explanation | COST |
|---|--|--|--|
| <u>Diagnosis:</u> Ocular | Consultation | ±7 per year in basket | Basic + dilated examination 0190 3009 3014 3004 0201 (drops) |
| | OCT | ± 7 per year / eye | 3028 L + R |
| Angiogram | Photo To assess ischaemia and leakage | 0 - 1 | 3027 L + R FANG 0190 3003 3022 3024 3027 |
| Systemically | Medical assessment: incl. HBA1C levels Diabetic clinic attendance | Medical assessment | |
| <u>Treatment:</u> Loading dose with anti-VEGF agent | 5 - 6 monthly injections may be needed in DMO before adequate response (per eye) | Avastin | 3035, 3090 Dr's fee per injection + drug Facility fee per eye |
| Follow up after loading - maintenance regime | | Avastin monthly or alternate regimens: Treat and extend or prn treatment | Same as loading |
| <u>Switch</u> to alternative agents | Lucentis, Eylea or Ozurdex | Second line agent - Lucentis or Eylea/ Ozurdex or Triamcinolone | Cost of Lucentis or Eylea / Ozurdex / Triamcinolone |
| Angiography - fluorescein | Yes To assess ischaemia if poor response to treatment | Depends on response to treatment | FANG + facility fee 0190 3003 3022 3024 3027 |
| Angiography - ICG | No | No | |
| Laser | Macular laser or PRP | Used as an adjunct to intravitreal treatment | 3039 or 3041 + 3201 |
| Duration of treatment | Depends on activity i.e. vision OCT activity | Regime: Treat and extend or prn treatment | Guideline 1st year ± 9 treatments 2nd year ± 7 treatments Consult + OCT with each assessment |
| Stopping treatment | | Stop if no improvement / futile e.g. scarring | |
| Follow up | Lifelong Continued medical management | Yes | |

PRP = panretinal photocoagulation